Axa
NVO

Axa’s Novo Nordisk NVO Stock Holding History

Axa’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-267,933
Closed -$18.5M – 724
2025
Q2 		$18.5M Buy
267,933
+130,406
+95% +$8.87M 0.05% 292
2025
Q1 		$9.55M Sell
137,527
-30,668
-18% -$2.53M 0.03% 393
2024
Q4 		$14.5M Buy
168,195
+61,040
+57% +$6.6M 0.04% 325
2024
Q3 		$12.8M Buy
+107,155
New +$14.3M 0.04% 355
2022
Q2 		– Sell
-3,794
Closed -$211K – 1182
2022
Q1 		$211K Buy
+3,794
New +$195K ﹤0.01% 1148
2021
Q1 		– Sell
-2,612
Closed -$91K – 1297
2020
Q4 		$91K Buy
2,612
+124
+5% +$4.29K ﹤0.01% 1204
2020
Q3 		$86K Buy
+2,488
New +$82.9K ﹤0.01% 1202

Other funds holding NVO

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Axa's NVO Position: Q3 2025 in Review

Axa sold out of Novo Nordisk (NVO) in Q3 2025, closing a stake of 267,933 shares — an estimated $18.5M sold.

Axa first reported a position in NVO in Q3 2020 and held it in 7 quarters. The position peaked at $18.5M in Q2 2025. 1,395 funds tracked by Wall St. Rank hold NVO as of Q3 2025.

  • Axa reported no remaining Novo Nordisk position as of Q3 2025 after selling out during the quarter.
  • Axa sold 267,933 Novo Nordisk shares in Q3 2025, an estimated $18.5M.
  • Axa first reported a position in Novo Nordisk in Q3 2020 and held it in 7 quarters.
  • Axa's Novo Nordisk position peaked at $18.5M in Q2 2025.
  • 1,395 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2025.

Based on Axa's 13F filing for Q3 2025, filed 14 Nov 2025.